Tuesday, August 22, 2017 3:54:10 PM
Worth repeating:
Quote:
Why not just one year to show good faith instead of four long years? Management knows they don't have the resources for Phase 3s. That's why they're trying to partner. Here's a brief summary of the drug candidates.
B-UP: In the Phase 2 POC trial, the drug achieved 67% clinical remission as evident by endoscopic images. Every patient had improvement in quality-of-life. IBD is a hot market. J&J recently agreed to a $990M deal with $50M upfront payment to acquire Protagonist's PRECLINICAL oral IBD drug.
B-OM: Interim analysis was very encourging with severe OM prevention in 78% of patients. The current standard of care only shortens the duration of severe OM but doesn't prevent it. Patient enrollment is 100% and the top-line result is expected in October/November. The FDA granted Fast Track Designation and IPIX plans to apply for Breakthrough Therapy Designation if the trial is successful.
B-ABSSSI: Single dose matched 7-day Daptomycin in Phase 2b. If IPIX can find a partner for other drugs, they'll advance the drug to Phase 3 using the upfront money.
P: In the Phase 2a trial, 35% of mild/moderate psoriasis patients in the 200 mg arm achieved at least a 2-point IGA improvement. Sub-population analysis shows 46% of moderate psoriasis patients in the 200 mg arm achieved at least a 2-point IGA improvment. The dosage has increased to 300 mg and 400 mg in the Phase 2b trial. It'll assess moderate/severe psoriasis patients using an easier scale in PASI 75. The FDA granted the 505(b)(2) pathway, so only one Phase 3 with fewer patients might be required. The bar isn't set very high by Otezla with ~30% PASI 75. Interim analysis is expected in Q3 and top-line result is expected in Q4.
K-OC: K is the riskiest but has the most potential. The drug was shown to be safe in Phase 1 with 67.5% of patients had increases in p21 expression. Big name immunotherapy drugs such as Opdivo failed a key Phase 3 trial in lung cancer and Keytruda was halted due to patient deaths. The main purpose of this Phase 2 trial is to confirm K's MOA as requested by an interested party. A safe p53-activating drug could be very valuable.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM